secwatch.observer — SEC 8-K summary
======================================

Issuer:     FENNEC PHARMACEUTICALS INC. (FENC)
CIK:        0001211583
Form:       8-K
Filed at:   2022-08-01T23:59:59+00:00
Accession:  0001558370-22-011467
Event type: debt
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.03, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fennec secures up to $45M from Petrichor; $5M now, $20M on FDA approval of PEDMARK
--------------------------------------------------------------------------------

- Petrichor invests $5M in convertible notes at $8.11/share; $20M additional due upon FDA approval of PEDMARK by Sep 30, 2022.
- Notes: US Prime +4.5% interest, 3.5% PIK for 24 months, maturity Aug 1, 2027; company will repay Bridge Bank debt.
- Potential $20M more available before Dec 31, 2023; funds support PEDMARK launch for cisplatin-induced ototoxicity.
- PEDMARK PDUFA target action date is Sep 23, 2022; first FDA-approved therapy to reduce ototoxicity risk.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1211583/000155837022011467/0001558370-22-011467-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1211583/000155837022011467/fencf-20220801x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-011467

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer